Medicxi Ventures Management (Jersey) Ltd

Q2 2022 13F Holdings Report, Restatement, Stock Holdings

Notable people
Francesco De Rubertis, Kevin Stuart Johnson, Michele Ollier
Signature - Title
Giles Johnstone-Scott - Director
Location
St. Helier, Jersey
Holdings as of
June 30, 2022
Value $
$241M
Num holdings
6
Date filed
8/3/2022, 11:09 AM
Description
All US holdings of this investor are reported in this report. The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q1 2022 - May 12, 2022
Next filing
Q3 2022 - Oct 25, 2022
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2022 Q2 - Restatement compared to 2022 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Giles Johnstone-Scott Director St. Helier, Jersey 8/3/2022

Amendment being filed to include the number of Phathom Pharmaceuticals shares under Column 8 for the number of voting securities and is the only basis for being a "restatement".

Other Included Managers (1):

Num Name File Number
1 Francesco De Rubertis